Clinical trial · Observational
Cancer DNA Detection in Blood and Urine
Non-invasive Detection of Cancer DNA in Blood and Urine
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is being conducted to collect and analyze biospecimens (blood and urine) and clinical data from patients with prostate cancer as well as healthy volunteers to better understand the differences between cancer cells and normal tissues with the goal of developing a better way to detect and track the treatment of prostate cancer. * These samples are being collected to conduct research to accomplish the goal of improving cancer therapies, biomarkers, and hopefully lead to more effective treatment of prostate cancer. * The samples that you are providing as a patient with prostate cancer will be used in future research. * Your biospecimens will be compared to the cancer and normal volunteer specimens from other participants to understand genetic differences between normal and cancer cells. Genetic material, including DNA and RNA, will be obtained from samples, stored, and used for evaluation. * Clinical information and samples will be collected and stored for ongoing research. This is a necessity because improved diagnosis, prognosis and treatment of cancer in the future depend upon the ongoing analysis of basic research findings and clinical outcomes. This type of research may improve the lives of future patients with cancer. Men between the ages of 18 and 100 with a diagnosis of cancer undergoing standard therapy with radiation may join.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Urine collection and blood draw | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Healthy volunteer
- description
- Normal volunteers will be enrolled and informed consent obtained per study guidelines as described. Urine and plasma will be collected from each of 30 subjects with no prior history of prostate or other cancers.
- label
- Prostate cancer patients being treat with radiation therapy
- description
- Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 25 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to the onset of therapy.
- label
- Prostate cancer patients being treated with radiation therapy
- description
- Prostate cancer patients will be enrolled and informed consent obtained per study guidelines as described. We will collect urine and plasma samples from 5 consecutive men being treated with radiation therapy for high-risk prostate cancer prior to initiation of androgen deprivation (week 0), again prior to initiation of radiotherapy (week 8), at the end of radiation therapy (week 16) and at 6 months and 12 months after the conclusion of radiation therapy.
- interventionNames
- Procedure: Urine collection and blood draw
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male older than or equal to 18 years of age, but not older than 100 years of age. 2. Signed informed consent prior to initiation of any study-related procedures. 3. Minorities are included in this protocol. 4. Signed informed consent prior to initiation of any study-related Exclusion Criteria: 1. It is the enrolling study physician's discretion to decide if a patient is not fit enough to undergo procedures outlined in this protocol. 2. Persons who are incarcerated are not eligible to participate. 3. Women are not eligible. 4. Persons incapable of providing informed consent are not eligible. 5. Any person with a personal history of prior malignancy is not eligible 6. Persons with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome are not eligible.
References
Publications (0)
Data not yet available